Skip to content

Study · Case report or series · n = 1 · 2022

1 result

Liraglutide Overdose-Induced Acute Pancreatitis.

AlSaadoun AR, AlSaadoun TR, Al Ghumlas AK

Cureus25 Jan 2022Cited by 8 (Europe PMC)

PMID35228970 (opens in a new tab)PMCIDPMC8874232 (opens in a new tab)DOI10.7759/cureus.21616 (opens in a new tab)PepBankPUB-35228970
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Liraglutide, a long-acting cardioprotective glucagon-like peptide (GLP)-1 analog, is effective for medical weight loss and glycemic control in type 2 diabetes. It is generally well tolerated with mild side effects. There are few reports on complications from Liraglutide overdose. The aim of this paper is to report the case of a 25-year-old healthy female who presented with acute pancreatitis secondary to Liraglutide overdose and to review the current literature on Liraglutide used for obesity management. The current literature examining the association between acute pancreatitis and Liraglutide use, and Liraglutide overdose are inconclusive. Further research is recommended.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 25-year-old healthy woman, a liraglutide overdose was followed by acute pancreatitis.

    In plain wordsIn one 25-year-old healthy woman, taking too much liraglutide was followed by inflammation of the pancreas.

    Peptide
    Liraglutide
    Outcome
    IncreaseAcute pancreatitis after liraglutide overdose
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    report the case of a 25-year-old healthy female who presented with acute pancreatitis secondary to Liraglutide overdose
    1 context sentence
    Title · context
    Liraglutide Overdose-Induced Acute Pancreatitis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.